María del Carmen Durand-Vásquez
María del Carmen Durand-Vásquez has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Juan Eduardo Quiroz-Aldave
Hospital de apoyo Chepén
13 shared publications - Marcio José Concepción-Zavaleta
Universidad Científica del Sur
12 shared publications - Luis Alberto Concepción-Urteaga
Universidad Nacional de Trujillo
11 shared publications - José Paz-Ibarra
Universidad Nacional Mayor de San Marcos
9 shared publications - Elman Rolando Gamarra-Osorio
Division of Endocrinology, Hospital Víctor Lazarte Echegaray, Trujillo, Peru
6 shared publications - Cristian David Armas Flórez
Division of Internal Medicine, Eastern Virginia Medical School at Old Dominion University, Norfolk, VA, USA
2 shared publications
Latest Publications
- 6 April 2026
- Published by Springer Nature in Current Treatment Options in Psychiatry
- Vol. 13 (1) , 9
Endocrine Disorders and Psychiatric Symptoms: A Comprehensive Overview
- 6 April 2026
- Published by Springer Nature in Current Treatment Options in Psychiatry
- Vol. 13 (1) , 9
Endocrine Disorders and Psychiatric Symptoms: A Comprehensive Overview
- Open Access
- 1 July 2025
- Published by Modestum Ltd in Electronic Journal of General Medicine
- Vol. 22 (4) , em653
The diagnosis of LADA diabetes in a low-resource country: A Peruvian case series
Introduction: Diabetes mellitus (DM) is a global public health concern, affecting 10% of adults. Among its variants, latent autoimmune diabetes in adults (LADA) accounts for 3% to 11% of cases. Limited awareness and high testing costs contribute to misdiagnosis and inadequate treatment, increasing the risk of chronic complications. Design: A cases series. Methods: Fifteen Peruvian patients with LADA were studied to describe their clinical presentation, diagnosis, and treatment. Results: The average age was 36.2 years, with a mean disease duration of 5.6 years. All patients presented with acute symptoms, and their mean body mass index at diagnosis was 23.3 kg/m². Glycemic control was achieved with an average daily insulin dose of 0.96 IU/kg. None of the patients had access to capillary glucose self-monitoring or continuous glucose monitoring, as all were living in poverty or extreme poverty. Conclusions: LADA is an uncommon form of early-onset DM whose diagnosis and treatment in resource-limited countries are impacted by socioeconomic conditions. Therefore, we propose a clinical algorithm for managing this condition in low-resource settings.
- 1 July 2025
- Published by Modestum Ltd in Electronic Journal of General Medicine
- Vol. 22 (4) , em653
Open AccessThe diagnosis of LADA diabetes in a low-resource country: A Peruvian case series
Introduction: Diabetes mellitus (DM) is a global public health concern, affecting 10% of adults. Among its variants, latent autoimmune diabetes in adults (LADA) accounts for 3% to 11% of cases. Limited awareness and high testing costs contribute to misdiagnosis and inadequate treatment, increasing the risk of chronic complications. Design: A cases series. Methods: Fifteen Peruvian patients with LADA were studied to describe their clinical presentation, diagnosis, and treatment. Results: The average age was 36.2 years, with a mean disease duration of 5.6 years. All patients presented with acute symptoms, and their mean body mass index at diagnosis was 23.3 kg/m². Glycemic control was achieved with an average daily insulin dose of 0.96 IU/kg. None of the patients had access to capillary glucose self-monitoring or continuous glucose monitoring, as all were living in poverty or extreme poverty. Conclusions: LADA is an uncommon form of early-onset DM whose diagnosis and treatment in resource-limited countries are impacted by socioeconomic conditions. Therefore, we propose a clinical algorithm for managing this condition in low-resource settings.
- Open Access
- 25 March 2025
- Published by Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo in Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
- Vol. 18 (1) , e2677
Primer caso reportado en Perú de cetoacidosis euglicémica por inhibidor del cotransportador de sodio glucosa tipo 2
Introducción: La cetoacidosis diabética euglicémica (CADeu) representa hasta el 7% de los casos de cetoacidosis diabética (CAD), y se presenta con glicemia menor a 200 mg/d. Se ha asociado con el uso de inhibidores del cotransportador de sodio-glucosa tipo 2 (iSGLT-2). Reporte de caso: Presentamos el caso de un varón de 34 años con obesidad y diabetes tipo 2, quien 4 días antes del ingreso inicia tratamiento con empagliflozina/metformina 12.5/1000 mg BID por glucemias superiores a 350 mg/dl. Ingresó a emergencia con un cuadro compatible con CAD y glicemia de 180 mg/dL. Fue manejado con hidratación e insulinoterapia, logrando una mejoría significativa. Discusión: La glicemia en la CADeu suele ser de 184.5 mg/dL con falsos negativos en los cuerpos cetónicos en orina, lo que puede retrasar en su diagnóstico. El tratamiento incluye la suspensión del iSGLT-2, reposición de líquidos, corrección de electrolitos y administración de insulina. Es importante mejorar el reconocimiento de esta enfermedad para un diagnóstico precoz y manejo oportuno.
- 25 March 2025
- Published by Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo in Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
- Vol. 18 (1) , e2677
Open AccessPrimer caso reportado en Perú de cetoacidosis euglicémica por inhibidor del cotransportador de sodio glucosa tipo 2
Introducción: La cetoacidosis diabética euglicémica (CADeu) representa hasta el 7% de los casos de cetoacidosis diabética (CAD), y se presenta con glicemia menor a 200 mg/d. Se ha asociado con el uso de inhibidores del cotransportador de sodio-glucosa tipo 2 (iSGLT-2). Reporte de caso: Presentamos el caso de un varón de 34 años con obesidad y diabetes tipo 2, quien 4 días antes del ingreso inicia tratamiento con empagliflozina/metformina 12.5/1000 mg BID por glucemias superiores a 350 mg/dl. Ingresó a emergencia con un cuadro compatible con CAD y glicemia de 180 mg/dL. Fue manejado con hidratación e insulinoterapia, logrando una mejoría significativa. Discusión: La glicemia en la CADeu suele ser de 184.5 mg/dL con falsos negativos en los cuerpos cetónicos en orina, lo que puede retrasar en su diagnóstico. El tratamiento incluye la suspensión del iSGLT-2, reposición de líquidos, corrección de electrolitos y administración de insulina. Es importante mejorar el reconocimiento de esta enfermedad para un diagnóstico precoz y manejo oportuno.
- Open Access
- 17 February 2025
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 42 (1) , 97-101
Penfigoide bulloso asociado a vildagliptina en adulto mayor con diabetes mellitus: Primer caso en Perú
La vildagliptina, un inhibidor de la dipeptidil peptidasa-4 (DPP-4i) utilizado en el tratamiento de la diabetes mellitus tipo 2 (DM2), se destaca por su seguridad en adultos mayores. Sin embargo, se asocia con reacciones adversas, como el penfigoide ampollar (PA), aunque hasta el momento no se han documentado casos en Perú. Se reporta un paciente varón de 76 años con hipertensión y DM2 que inició tratamiento con vildagliptina y metformina. Después de un mes, presentó lesiones cutáneas pruriginosas, ampollosas y ulceradas, conduciendo al diagnóstico de PA. El PA, asociado a DPP-4i, afecta principalmente a adultos mayores, manifestándose en promedio unos 9 meses después del inicio del tratamiento. Su diagnóstico se basa en criterios clínicos, histopatología e inmunofluorescencia. El tratamiento incluye la suspensión del fármaco y el uso de corticoides. La vildagliptina, aunque segura y efectiva, puede provocar PA, que requiere un diagnóstico y tratamiento oportuno debido a su alta mortalidad.
- 17 February 2025
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 42 (1) , 97-101
Open AccessPenfigoide bulloso asociado a vildagliptina en adulto mayor con diabetes mellitus: Primer caso en Perú
La vildagliptina, un inhibidor de la dipeptidil peptidasa-4 (DPP-4i) utilizado en el tratamiento de la diabetes mellitus tipo 2 (DM2), se destaca por su seguridad en adultos mayores. Sin embargo, se asocia con reacciones adversas, como el penfigoide ampollar (PA), aunque hasta el momento no se han documentado casos en Perú. Se reporta un paciente varón de 76 años con hipertensión y DM2 que inició tratamiento con vildagliptina y metformina. Después de un mes, presentó lesiones cutáneas pruriginosas, ampollosas y ulceradas, conduciendo al diagnóstico de PA. El PA, asociado a DPP-4i, afecta principalmente a adultos mayores, manifestándose en promedio unos 9 meses después del inicio del tratamiento. Su diagnóstico se basa en criterios clínicos, histopatología e inmunofluorescencia. El tratamiento incluye la suspensión del fármaco y el uso de corticoides. La vildagliptina, aunque segura y efectiva, puede provocar PA, que requiere un diagnóstico y tratamiento oportuno debido a su alta mortalidad.
- 1 January 2025
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 25 (5) , 421-427
Diagnostic Role of Tomography in Addison's Disease due to Adrenal Tuberculosis: A Case Report
Introduction: Adrenal tuberculosis remains the main cause of primary adrenal insufficiency (PAI) in tuberculosis (TB)-prevalent regions. This case report details the presentation of PAI due to adrenal TB, where the etiological diagnosis involves Abdominal Computed Tomography (CT). Case Report: A 37-year-old Peruvian woman with a history of TB contact displayed symptoms of adrenal insufficiency. PAI diagnosis was established, and CT imaging unveiled bilateral adrenal enlargement with calcifications. Treatment with prednisone and anti-TB therapy led to symptomatic improvement. Unfortunately, she succumbed to pneumonia after ten months of follow-up. Discussion: Adrenal TB must be considered in endemic regions and in the presence of a TB history. CT serves as a valuable diagnostic tool, particularly in settings with limited resources, revealing adrenal enlargement and calcifications. Conclusion: In patients with PAI, epidemiological history of TB, and when a rapid biopsy is not feasible, CT proves to be a valuable diagnostic method.
- 1 January 2025
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 25 (5) , 421-427
Diagnostic Role of Tomography in Addison's Disease due to Adrenal Tuberculosis: A Case Report
Introduction: Adrenal tuberculosis remains the main cause of primary adrenal insufficiency (PAI) in tuberculosis (TB)-prevalent regions. This case report details the presentation of PAI due to adrenal TB, where the etiological diagnosis involves Abdominal Computed Tomography (CT). Case Report: A 37-year-old Peruvian woman with a history of TB contact displayed symptoms of adrenal insufficiency. PAI diagnosis was established, and CT imaging unveiled bilateral adrenal enlargement with calcifications. Treatment with prednisone and anti-TB therapy led to symptomatic improvement. Unfortunately, she succumbed to pneumonia after ten months of follow-up. Discussion: Adrenal TB must be considered in endemic regions and in the presence of a TB history. CT serves as a valuable diagnostic tool, particularly in settings with limited resources, revealing adrenal enlargement and calcifications. Conclusion: In patients with PAI, epidemiological history of TB, and when a rapid biopsy is not feasible, CT proves to be a valuable diagnostic method.
- Open Access
- 25 November 2024
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 41 (4) , 431-7
Tiroiditis subaguda post dengue en una mujer peruana: reporte de caso y revisión de la literatura
Expanded dengue syndrome are unusual conditions, such as subacute thyroiditis (SAT). We present the case of a 38-year-old woman who had dengue without alarm signs for a month, along with cervical pain and increased cervical volume, palpitations, tremor and dysphagia. Hormonal evaluation, ultrasound andthyroid scintigraphy were consistent with SAT. She received corticoids for two months, with remission afterfour months. SAT is characterized by neck pain, fever and symptoms of thyrotoxicosis. It is associated withviral infections and it comprises a phase of thyrotoxicosis followed by hypothyroidism. Diagnosis involves hormonal and biochemical tests, thyroid ultrasound with Doppler and scintigraphy. This condition is managed with non-steroidal anti-inflammatory drugs and corticosteroids, according to severity. SAT, an infrequent manifestation of dengue, requires a high degree of suspicion and appropriate management. A review of published cases of SAT due to dengue was carried out in the Scopus, PubMed and Web of Science databases, finding six reported cases, mostly in men.
- 25 November 2024
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- Vol. 41 (4) , 431-7
Open AccessTiroiditis subaguda post dengue en una mujer peruana: reporte de caso y revisión de la literatura
Expanded dengue syndrome are unusual conditions, such as subacute thyroiditis (SAT). We present the case of a 38-year-old woman who had dengue without alarm signs for a month, along with cervical pain and increased cervical volume, palpitations, tremor and dysphagia. Hormonal evaluation, ultrasound andthyroid scintigraphy were consistent with SAT. She received corticoids for two months, with remission afterfour months. SAT is characterized by neck pain, fever and symptoms of thyrotoxicosis. It is associated withviral infections and it comprises a phase of thyrotoxicosis followed by hypothyroidism. Diagnosis involves hormonal and biochemical tests, thyroid ultrasound with Doppler and scintigraphy. This condition is managed with non-steroidal anti-inflammatory drugs and corticosteroids, according to severity. SAT, an infrequent manifestation of dengue, requires a high degree of suspicion and appropriate management. A review of published cases of SAT due to dengue was carried out in the Scopus, PubMed and Web of Science databases, finding six reported cases, mostly in men.
- 23 January 2024
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 19 (3) , 199-206
Drug-induced hypothyroidism in tuberculosis
Introduction: Adverse reactions to tuberculosis treatment can impact patient adherence and prognosis. Hypothyroidism is a frequent adverse reaction caused using ethionamide, prothionamide, and para-aminosalicylic acid and is often underdiagnosed.Areas covered: We searched Scielo, Scopus, and EMBASE databases, including 67 articles. Antitubercular drug-induced hypothyroidism has a prevalence of 17%. It occurs after 2 to 3 months of treatment and resolves within 4 to 6 weeks after discontinuation. It is postulated to result from the inhibition of thyroperoxidase function, blocking thyroid hormone synthesis. Symptoms are nonspecific, necessitating individualized thyroid-stimulating hormone measurement for detection. Specific guidelines for management are lacking, but initiation of treatment with levothyroxine, as is customary for primary hypothyroidism, is recommended. Discontinuation of antitubercular drugs is discouraged, as it may lead to unfavorable consequences.Expert opinion: Antitubercular drug-induced hypothyroidism is more common than previously thought, affecting one in six MDR-TB patients. Despite diagnostic and treatment recommendations, implementation is hindered in low-income countries due to the lack of certified laboratories. New drugs for tuberculosis treatment may affect thyroid function, requiring vigilant monitoring for complications, including hypothyroidism.
- 23 January 2024
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 19 (3) , 199-206
Drug-induced hypothyroidism in tuberculosis
Introduction: Adverse reactions to tuberculosis treatment can impact patient adherence and prognosis. Hypothyroidism is a frequent adverse reaction caused using ethionamide, prothionamide, and para-aminosalicylic acid and is often underdiagnosed.Areas covered: We searched Scielo, Scopus, and EMBASE databases, including 67 articles. Antitubercular drug-induced hypothyroidism has a prevalence of 17%. It occurs after 2 to 3 months of treatment and resolves within 4 to 6 weeks after discontinuation. It is postulated to result from the inhibition of thyroperoxidase function, blocking thyroid hormone synthesis. Symptoms are nonspecific, necessitating individualized thyroid-stimulating hormone measurement for detection. Specific guidelines for management are lacking, but initiation of treatment with levothyroxine, as is customary for primary hypothyroidism, is recommended. Discontinuation of antitubercular drugs is discouraged, as it may lead to unfavorable consequences.Expert opinion: Antitubercular drug-induced hypothyroidism is more common than previously thought, affecting one in six MDR-TB patients. Despite diagnostic and treatment recommendations, implementation is hindered in low-income countries due to the lack of certified laboratories. New drugs for tuberculosis treatment may affect thyroid function, requiring vigilant monitoring for complications, including hypothyroidism.
- 1 December 2023
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 24 (1-2) , 5-14
Ifosfamide-induced nephrotoxicity in oncological patients
Ifosfamide is an alkylating chemotherapeutic agent used in the treatment of various neoplasms. Its main adverse effects include renal damage. A comprehensive review was conducted, including 100 articles from the Scielo, Scopus, and EMBASE databases. Ifosfamide-induced nephrotoxicity is attributed to its toxic metabolites, such as acrolein and chloroacetaldehyde, which cause mitochondrial damage and oxidative stress in renal tubular cells. Literature review found a 29-year average age with no gender predominance and a mortality of 13%. Currently, no fully effective strategy exists for preventing ifosfamide-induced nephrotoxicity; however, hydration, forced diuresis, and other interventions are employed to limit renal damage. Long-term renal function monitoring is essential for patients treated with ifosfamide. Ifosfamide remains essential in neoplasm treatment, but nephrotoxicity, often compounded by coadministered drugs, poses diagnostic challenges. Preventive strategies are lacking, necessitating further research. Identifying timely risk factors can mitigate renal damage, and a multidisciplinary approach manages established nephrotoxicity. Emerging therapies may reduce ifosfamide induced nephrotoxicity.
- 1 December 2023
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 24 (1-2) , 5-14
Ifosfamide-induced nephrotoxicity in oncological patients
Ifosfamide is an alkylating chemotherapeutic agent used in the treatment of various neoplasms. Its main adverse effects include renal damage. A comprehensive review was conducted, including 100 articles from the Scielo, Scopus, and EMBASE databases. Ifosfamide-induced nephrotoxicity is attributed to its toxic metabolites, such as acrolein and chloroacetaldehyde, which cause mitochondrial damage and oxidative stress in renal tubular cells. Literature review found a 29-year average age with no gender predominance and a mortality of 13%. Currently, no fully effective strategy exists for preventing ifosfamide-induced nephrotoxicity; however, hydration, forced diuresis, and other interventions are employed to limit renal damage. Long-term renal function monitoring is essential for patients treated with ifosfamide. Ifosfamide remains essential in neoplasm treatment, but nephrotoxicity, often compounded by coadministered drugs, poses diagnostic challenges. Preventive strategies are lacking, necessitating further research. Identifying timely risk factors can mitigate renal damage, and a multidisciplinary approach manages established nephrotoxicity. Emerging therapies may reduce ifosfamide induced nephrotoxicity.
- 19 September 2023
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 20 (1) , 26-39
A comprehensive review of genetic causes of obesity
Background Obesity is a multifactorial chronic disease with a high, increasing worldwide prevalence. Genetic causes account for 7% of the cases in children with extreme obesity. Data sources This narrative review was conducted by searching for papers published in the PubMed/MEDLINE, Embase and SciELO databases and included 161 articles. The search used the following search terms: “obesity”, “obesity and genetics”, “leptin”, “Prader-Willi syndrome”, and “melanocortins”. The types of studies included were systematic reviews, clinical trials, prospective cohort studies, cross-sectional and prospective studies, narrative reviews, and case reports. Results The leptin-melanocortin pathway is primarily responsible for the regulation of appetite and body weight. However, several important aspects of the pathophysiology of obesity remain unknown. Genetic causes of obesity can be grouped into syndromic, monogenic, and polygenic causes and should be assessed in children with extreme obesity before the age of 5 years, hyperphagia, or a family history of extreme obesity. A microarray study, an analysis of the melanocortin type 4 receptor gene mutations and leptin levels should be performed for this purpose. There are three therapeutic levels: lifestyle modifications, pharmacological treatment, and bariatric surgery. Conclusions Genetic study technologies are in constant development; however, we are still far from having a personalized approach to genetic causes of obesity. A significant proportion of the affected individuals are associated with genetic causes; however, there are still barriers to its approach, as it continues to be underdiagnosed. Video Abstract (MP4 1041807 KB)
- 19 September 2023
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 20 (1) , 26-39
A comprehensive review of genetic causes of obesity
Background Obesity is a multifactorial chronic disease with a high, increasing worldwide prevalence. Genetic causes account for 7% of the cases in children with extreme obesity. Data sources This narrative review was conducted by searching for papers published in the PubMed/MEDLINE, Embase and SciELO databases and included 161 articles. The search used the following search terms: “obesity”, “obesity and genetics”, “leptin”, “Prader-Willi syndrome”, and “melanocortins”. The types of studies included were systematic reviews, clinical trials, prospective cohort studies, cross-sectional and prospective studies, narrative reviews, and case reports. Results The leptin-melanocortin pathway is primarily responsible for the regulation of appetite and body weight. However, several important aspects of the pathophysiology of obesity remain unknown. Genetic causes of obesity can be grouped into syndromic, monogenic, and polygenic causes and should be assessed in children with extreme obesity before the age of 5 years, hyperphagia, or a family history of extreme obesity. A microarray study, an analysis of the melanocortin type 4 receptor gene mutations and leptin levels should be performed for this purpose. There are three therapeutic levels: lifestyle modifications, pharmacological treatment, and bariatric surgery. Conclusions Genetic study technologies are in constant development; however, we are still far from having a personalized approach to genetic causes of obesity. A significant proportion of the affected individuals are associated with genetic causes; however, there are still barriers to its approach, as it continues to be underdiagnosed. Video Abstract (MP4 1041807 KB)
- 13 September 2023
- Published by Elsevier in Endocrine Practice
- Vol. 29 (12) , 1007-1016
Refractory Hypothyroidism: Unraveling the Complexities of Diagnosis and Management
- 13 September 2023
- Published by Elsevier in Endocrine Practice
- Vol. 29 (12) , 1007-1016
Refractory Hypothyroidism: Unraveling the Complexities of Diagnosis and Management